Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06997029 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Advanced Breast Cancer, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 1
Development phase
234
Enrollment target
20
Study locations

NCT06997029 is a Phase 1 study of Advanced Solid Tumor and Advanced Breast Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 234 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06997029, a Phase 1 study of Advanced Solid Tumor and Advanced Breast Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 1
Development phase
234 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

Conditions Studied

Advanced Solid Tumor Advanced Breast Cancer Advanced Ovarian Cancer

Interventions

  • DRUG Fulvestrant
  • DRUG Palbociclib
  • DRUG BMS-986500

Study Locations (20)

California

  • Providence St. Jude Medical Center - Fullerton
  • Marin Cancer Care - Greenbrae
  • Moores Cancer Center - La Jolla
  • Hoag Memorial Hospital Presbyterian - Newport Beach

New York

  • Local Institution - 0014 - Buffalo
  • Northwell Health-Cancer Institute - New Hyde Park
  • Local Institution - 0011 - New York
  • Memorial Sloan Kettering Cancer Center - New York

Texas

  • START Dallas Fort Worth - Fort Worth
  • NEXT Oncology - San Antonio

Alabama

  • University of Alabama at Birmingham - Birmingham

Colorado

  • Local Institution - 0008 - Aurora

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Missouri

  • Washington University School of Medicine - St Louis

New Hampshire

  • Dartmouth-Hitchcock Medical Center - Lebanon

Trial Details

FieldValue
Enrollment Target 234 participants
Start Date 2025-08-01
Est. Completion 2028-12-14
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06997029

The ClinicalTrials.gov registry entry for NCT06997029 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Fulvestrant is the first listed.

NCT06997029 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, New York, Texas.

Frequently Asked Questions

What is clinical trial NCT06997029 about?

NCT06997029 is a clinical study titled "A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors". The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

What is the current status of trial NCT06997029?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 234 participants. The study started on 2025-08-01. Estimated completion is 2028-12-14.

What conditions does trial NCT06997029 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer.

What interventions are being tested in trial NCT06997029?

The interventions under investigation include: Fulvestrant (DRUG), Palbociclib (DRUG), BMS-986500 (DRUG).

Who is sponsoring clinical trial NCT06997029?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06997029 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Advanced Breast Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.